- Home
- CAN vs CRMD Comparison
CAN vs CRMD Comparison
Compare CAN & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | CRMD |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 876.7M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CAN | CRMD |
|---|---|---|
| Price | $0.77 | $11.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $3.56 | ★ $17.43 |
| AVG Volume (30 Days) | ★ 23.9M | 2.8M |
| Earning Date | 11-18-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | ★ $422,228,000.00 | $214,303,672.00 |
| Revenue This Year | $91.42 | $627.89 |
| Revenue Next Year | $47.07 | $40.95 |
| P/E Ratio | ★ N/A | $5.08 |
| Revenue Growth | 83.87 | ★ 1647.67 |
| 52 Week Low | $0.53 | $5.60 |
| 52 Week High | $3.19 | $17.43 |
Technical Indicators
Market Signals| Indicator | CAN | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 64.47 |
| Support Level | $0.76 | $11.04 |
| Resistance Level | $0.85 | $11.92 |
| Average True Range (ATR) | 0.06 | 0.51 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 6.32 | 94.48 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.